Nasopharyngeal Carcinoma
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Nasopharyngeal Carcinoma

What is the definition of Nasopharyngeal Carcinoma?
Nasopharyngeal carcinoma (NPC) is a tumor arising from the epithelial cells that cover the surface and line the nasopharynx.
What are the alternative names for Nasopharyngeal Carcinoma?
  • Nasopharyngeal carcinoma
  • Nasopharyngeal Cancer
Who are the top Nasopharyngeal Carcinoma Local Doctors?
Elite in Nasopharyngeal Carcinoma
Elite in Nasopharyngeal Carcinoma
Referral may be required
Department Of Head And Neck Surgery, 
Singapore, SG 

Melvin Chua practices practicing medicine in Singapore, Singapore. Mr. Chua is rated as an Elite expert by MediFind in the treatment of Nasopharyngeal Carcinoma. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Nasopharyngeal Carcinoma, Prostate Cancer, Mononucleosis, Dry Mouth, and Prostatectomy.

Elite in Nasopharyngeal Carcinoma
Radiation Oncology | Otolaryngology
Elite in Nasopharyngeal Carcinoma
Radiation Oncology | Otolaryngology
Referral may be required

Melanoma & Skin Cancer Center

1825 Fourth Street, Third Floor, 
San Francisco, CA 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Dr. Sue Yom is an expert in the radiation treatment and management of head, neck and lung cancers. In her research, Yom studies chemoradiation (a combination of chemotherapy and radiation) for these cancers. She also investigates image-guided radiation therapy and ways to reduce toxic effects using focused radiation techniques, emerging biological agents and radiation protectants. Yom earned her medical and doctoral degrees at the University of Pennsylvania. She completed a residency in radiation oncology at the MD Anderson Cancer Center. Yom has received numerous awards recognizing her commitment to patient care and patient-oriented research. Dr. Yom is rated as an Elite provider by MediFind in the treatment of Nasopharyngeal Carcinoma. She is also highly rated in 28 other conditions, according to our data. Her clinical expertise encompasses Nasopharyngeal Carcinoma, Olfactory Neuroblastoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Merkel Cell Carcinoma, and Laryngectomy. Dr. Yom is board certified in American Board Of Radiology, Radiation Oncology. Dr. Yom is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Nasopharyngeal Carcinoma
Elite in Nasopharyngeal Carcinoma
Referral may be required

ASST Spedali Civili Di Brescia

Brescia, IT 

Paolo Bossi practices practicing medicine in Brescia, Italy. Mr. Bossi is rated as an Elite expert by MediFind in the treatment of Nasopharyngeal Carcinoma. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Nasopharyngeal Carcinoma, Adenoid Cystic Carcinoma, Laryngectomy, and Endoscopy.

What are the latest Nasopharyngeal Carcinoma Clinical Trials?
A Phase 2 Window of Opportunity Trial of Neoadjuvant Agonistic Anti-CD40 Antibody CDX-1140 and Cemiplimab (REGN2810) in AJCC Stage III-IV Head and Neck Cancer Patients Prior to Surgery

Summary: This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. CDX-1140 is a monoclonal antibo...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2 Study Using Chemoimmunotherapy With Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)

Summary: This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, wo...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center